Healthpeak Properties (DOC) 주식 개요
는 미국에서 의료 서비스 발견 및 제공에 중점을 둔 고품질 부동산을 소유, 운영 및 개발하는 스탠더드앤드푸어스 500대 기업입니다. 자세히 보기
DOC Community Fair Values
Create NarrativeSee what 48 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Healthpeak Properties, Inc. 경쟁사
가격 이력 및 성과
| 과거 주가 | |
|---|---|
| 현재 주가 | US$21.89 |
| 52주 최고가 | US$21.98 |
| 52주 최저가 | US$15.70 |
| 베타 | 1.03 |
| 1개월 변동 | 12.55% |
| 3개월 변동 | 32.51% |
| 1년 변동 | 20.14% |
| 3년 변동 | 5.65% |
| 5년 변동 | -35.96% |
| IPO 이후 변동 | 312.05% |
최근 뉴스 및 업데이트
내러티브 업데이트 • Jun 26
DOC: Buybacks And Raised Earnings Guidance Will Support Measured Future Upside Potential
Analysts have slightly increased their price target on Healthpeak Properties to $21.44 from $20.83, citing updated assumptions around revenue growth, profit margins, the discount rate, and future P/E levels. What's in the News for Healthpeak Properties Healthpeak Properties reported a share repurchase activity from January 1, 2026 to May 5, 2026, buying back 5,950,000 shares for US$100 million, representing 0.86% of its shares, according to a buyback tranche update.Seeking Alpha • Jun 19
Healthpeak Properties: This 6% Yielding REIT Has More Room To Run
Summary Healthpeak Properties remains a Strong Buy, combining value, income, and recovery potential in healthcare real estate. DOC’s outpatient medical and life sciences segments show improving occupancy, strong lease spreads, and embedded rent escalators supporting steady growth. The Janus Living spin-off unlocks value in senior housing, with DOC retaining 82% ownership and benefiting from high segment growth. DOC offers a 6.2% yield, BBB+ balance sheet, and trades at 11.2x forward P/FFO, well below its historical average. Read the full article on Seeking Alpha
내러티브 업데이트 • Jun 12
DOC: Raised 2026 Outlook And Buybacks Will Conceal Mounting Margin Risks
Analysts have adjusted their price target on Healthpeak Properties from $16.00 to $17.00, tying the change to updated assumptions around discount rates, revenue trends, profit margins, and future P/E expectations. What's in the News Healthpeak Properties reported first quarter 2026 funds from operations as adjusted (FFOA) of $0.45 per share, which was above analyst estimates, supported by steady leasing momentum.Recent updates
내러티브 업데이트 • Jun 26
DOC: Buybacks And Raised Earnings Guidance Will Support Measured Future Upside Potential
Analysts have slightly increased their price target on Healthpeak Properties to $21.44 from $20.83, citing updated assumptions around revenue growth, profit margins, the discount rate, and future P/E levels. What's in the News for Healthpeak Properties Healthpeak Properties reported a share repurchase activity from January 1, 2026 to May 5, 2026, buying back 5,950,000 shares for US$100 million, representing 0.86% of its shares, according to a buyback tranche update.Seeking Alpha • Jun 19
Healthpeak Properties: This 6% Yielding REIT Has More Room To Run
Summary Healthpeak Properties remains a Strong Buy, combining value, income, and recovery potential in healthcare real estate. DOC’s outpatient medical and life sciences segments show improving occupancy, strong lease spreads, and embedded rent escalators supporting steady growth. The Janus Living spin-off unlocks value in senior housing, with DOC retaining 82% ownership and benefiting from high segment growth. DOC offers a 6.2% yield, BBB+ balance sheet, and trades at 11.2x forward P/FFO, well below its historical average. Read the full article on Seeking Alpha내러티브 업데이트 • Jun 12
DOC: Raised 2026 Outlook And Buybacks Will Conceal Mounting Margin Risks
Analysts have adjusted their price target on Healthpeak Properties from $16.00 to $17.00, tying the change to updated assumptions around discount rates, revenue trends, profit margins, and future P/E expectations. What's in the News Healthpeak Properties reported first quarter 2026 funds from operations as adjusted (FFOA) of $0.45 per share, which was above analyst estimates, supported by steady leasing momentum.내러티브 업데이트 • May 29
DOC: Buybacks And Higher Earnings Guidance Will Support Measured Future Upside Potential
Analysts have nudged their price target for Healthpeak Properties from about $20.17 to roughly $20.83, reflecting updated views on fair value, discount rate, revenue growth, profit margin and future P/E assumptions. What's in the News Healthpeak Properties reported repurchasing 5,950,000 shares for US$100 million between January 1, 2026 and May 5, 2026, representing 0.86% of its shares under the ongoing buyback program announced on July 25, 2024 (Key Developments).내러티브 업데이트 • May 13
DOC: Buyback Activity And Raised Earnings Outlook Will Mask Weaker Margin Outlook
Analysts have kept their $16.00 price target on Healthpeak Properties unchanged, citing updated assumptions that include a slightly higher discount rate, a shift to declining revenue growth, lower profit margins, and a much higher future P/E estimate. What's in the News From January 1, 2026 to May 5, 2026, Healthpeak Properties repurchased 5,950,000 shares, representing 0.86% of its stock for US$100 million under its existing buyback program (Key Developments).
내러티브 업데이트 • Apr 28
DOC: Higher Margins And Earnings Outlook Will Support Future Upside Potential
Analysts have trimmed their price target on Healthpeak Properties by about $0.64 to $25.80 as updated assumptions for fair value, discount rate, revenue growth, profit margin, and future P/E are incorporated into their models. What's in the News Healthpeak Properties reported that from October 1, 2025 to December 31, 2025, it repurchased 0 shares for $0 million under its existing buyback program, closing out a total repurchase of 5,091,156 shares, or 0.73%, for $94.17 million under the authorization announced on July 25, 2024 (Key Developments).내러티브 업데이트 • Apr 14
DOC: Share Repurchases And Improved Margins Will Support Future Upside Potential
Analysts have slightly raised their price target on Healthpeak Properties to about $26.44, a marginal change from roughly $26.43. The revision reflects updated assumptions related to discount rate, revenue growth, profit margin and a projected future P/E near 98x.내러티브 업데이트 • Mar 31
DOC: Earnings Guidance And Completed Buyback Will Shape Measured Future Return Potential
Analysts now hold their $16.00 price target on Healthpeak Properties while adjusting underlying assumptions slightly on discount rate, revenue growth, profit margin, and future P/E. This reflects fine tuning rather than a major shift in their view of the stock.내러티브 업데이트 • Mar 16
DOC: Share Repurchases And Stronger Margins Will Support Future Upside Potential
Analysts now estimate Healthpeak Properties' fair value price target at about $26.43, compared with the previous estimate of roughly $26.71. The revision reflects updated views on revenue growth, profit margin and future P/E assumptions.내러티브 업데이트 • Mar 02
DOC: Earnings Outlook And Completed Buyback Will Highlight Limited Future Upside
Analysts have maintained their $16.00 price target for Healthpeak Properties. They cite only small adjustments to assumptions around discount rate, revenue growth, profit margin, and future P/E that together do not materially change their view of the stock’s valuation.내러티브 업데이트 • Feb 16
DOC: Share Buyback Completion And Earnings Outlook Will Shape Fair Prospects
Analysts have adjusted their price target on Healthpeak Properties from $18.00 to $16.00. The revision reflects updated models that incorporate a slightly higher discount rate, a lower profit margin assumption and a revised future P/E estimate, while also taking into account a higher revenue growth outlook.내러티브 업데이트 • Feb 02
DOC: Stable Margins And Modest Assumption Shifts Will Support Future Upside Potential
Analysts now estimate fair value for Healthpeak Properties at about US$20.17 per share, compared with roughly US$20.68 previously. The change reflects slightly revised assumptions around discount rates, long term revenue growth, profit margins and future P/E levels.내러티브 업데이트 • Jan 19
DOC: Share Repurchases And Higher Future P/E Will Support Upside Potential
Analysts have nudged their price target on Healthpeak Properties slightly higher to about US$26.71 from roughly US$26.65, citing updated assumptions for revenue growth, profit margins and a higher future P/E multiple. Together, these factors shape a modestly revised outlook for the shares.내러티브 업데이트 • Jan 05
DOC: Completed Buyback And Stable Margins Will Support Future Upside Potential
Analysts have trimmed their price target on Healthpeak Properties to about US$20.68 per share from roughly US$20.92, citing slightly higher discount rate assumptions along with modest adjustments to revenue growth, profit margin, and future P/E inputs in their models. What's in the News From July 1, 2025 to September 30, 2025, Healthpeak Properties reported no share repurchases under its current program, with 0 shares bought for US$0 million in that period (Key Developments).내러티브 업데이트 • Dec 14
DOC: Share Repurchases And Margin Outlook Will Support Future Upside Potential
Analysts have trimmed their price target on Healthpeak Properties to approximately $26.65 from about $27.73, reflecting slightly higher discount-rate assumptions and more modest revenue growth expectations, partially offset by improved profit margin and a lower projected future price to earnings multiple. What's in the News Completed repurchase of 5,091,156 shares for approximately $94.17 million under the buyback program announced on July 25, 2024, representing about 0.73% of shares (Key Developments) No additional shares were repurchased between July 1, 2025 and September 30, 2025 under the existing buyback tranche, with total spending of $0 million in the period (Key Developments) Removed from the FTSE All-World Index (USD), which may affect index-linked ownership and trading volumes for the stock (Key Developments) Valuation Changes Fair Value Estimate decreased slightly to approximately $26.65 from about $27.73.내러티브 업데이트 • Nov 30
DOC: Lower Discount Rate Will Support Improving Profit Margins Moving Forward
Analysts have modestly increased their price target for Healthpeak Properties from $20.86 to $20.92. This reflects slightly improved forward-looking profit margins and a lower discount rate, although it is partially tempered by a more conservative outlook for revenue growth.내러티브 업데이트 • Nov 16
DOC: Discount Rate Improvements Will Drive Margin Gains Ahead
Analysts have slightly lowered their price target for Healthpeak Properties from $21.03 to $20.86. They cite modest adjustments in growth and discount rate assumptions, while also noting a marginal improvement in profit margins.내러티브 업데이트 • Nov 01
DOC: Share Repurchase And Index Removal Will Unlock Future Upside Potential
Analysts have slightly lowered their price target for Healthpeak Properties to $21.03 from $21.19, citing modest reductions in revenue growth and profit margin expectations as key factors behind the revision. What's in the News Healthpeak Properties completed the repurchase of 5,091,156 shares, representing 0.73% of outstanding shares, for $94.17 million under its buyback announced on July 25, 2024 (Key Developments).내러티브 업데이트 • Oct 17
Outpatient And Life Science Trends Will Create Future Opportunities
Analysts have slightly lowered their price target for Healthpeak Properties from $21.31 to $21.19, citing a modest increase in expected discount rates and revenue growth, along with a small dip in projected profit margin. What's in the News Healthpeak Properties, Inc.내러티브 업데이트 • Oct 03
Outpatient And Life Science Trends Will Create Future Opportunities
Analysts have slightly revised their price target for Healthpeak Properties downward from $21.38 to $21.31. This change reflects minor updates to discount rate and valuation assumptions.내러티브 업데이트 • Sep 17
Outpatient And Life Science Trends Will Create Future Opportunities
Healthpeak Properties' fair value estimate edged only slightly lower as both its future P/E ratio and net profit margin saw negligible declines, resulting in a marginal decrease in the consensus analyst price target from $21.53 to $21.38. What's in the News Lowered full-year 2025 diluted EPS guidance to $0.25–$0.31 from $0.30–$0.36.내러티브 업데이트 • Sep 02
Outpatient And Life Science Trends Will Create Future Opportunities
The slight reduction in Healthpeak Properties’ future P/E ratio suggests a modestly improved earnings outlook relative to price, but with consensus revenue growth unchanged, analysts have only marginally decreased the fair value estimate from $21.72 to $21.53. What's in the News Healthpeak Properties lowered its full-year 2025 diluted EPS guidance to $0.25 – $0.31 from $0.30 – $0.36.내러티브 업데이트 • Aug 19
Outpatient And Life Science Trends Will Create Future Opportunities
Healthpeak Properties’ fair value saw a marginal decrease as a slight drop in its future P/E multiple reflected modestly softer forward expectations. What's in the News Completed share repurchase program, buying 5,091,156 shares (0.73%) for $94.17 million.Seeking Alpha • Apr 10
Healthpeak Properties: Defensive REIT With Strong Dividend And Post-Merger Upside
Summary Healthpeak Properties is a high-quality healthcare REIT trading at a low valuation, offering 25-30% price appreciation and a ~6.7% annual dividend yield. The successful merger with Physicians Realty Trust has created a dominant healthcare REIT with significant synergies, improving operational performance and tenant diversification. Healthpeak's portfolio benefits from a strong demographic tailwind, robust leasing activity, and strategic focus on outpatient medical buildings and life science properties. Trading at a lower valuation than peers, Healthpeak's strong fundamentals make it an attractive buy for total return and income-focused investors. Read the full article on Seeking AlphaSeeking Alpha • Mar 13
Why Healthpeak Is A Smart Buy For Income Investors
Summary Healthpeak Properties offers a compelling investment opportunity with a 5.9% dividend yield, strong operating fundamentals, and an attractive valuation. DOC's diversified healthcare portfolio benefits from limited new supply, robust demand, and strategic loan investments in life sciences for immediate earnings accretion. With a strong balance sheet and a forward P/FFO of 11.2, DOC is well-positioned for long-term growth and potential market-beating returns. Read the full article on Seeking AlphaSeeking Alpha • Jan 06
A REIT Geek Who Likes Healthpeak
Summary Healthpeak Properties is a top healthcare REIT with a robust portfolio, strong fundamentals, and a well-covered 6% yield, making it an attractive investment. Despite recent price declines, Healthpeak's AFFO growth, low leverage, and strategic life-science assets position it for stability and modest growth. The lab space market's tightening supply and increased biotech capital raise Healthpeak's valuation potential, justifying a conservative P/AFFO of 14-16x. At a share price of $16-$18, Healthpeak offers a compelling buy opportunity with an expected annualized return of 16-17%, supported by analyst consensus. Read the full article on Seeking AlphaSeeking Alpha • Dec 22
Healthpeak Properties: I'm Buying The 6% Dividend Yield
Summary Healthpeak Properties has dipped and now offers a 6% dividend yield that's 147% covered by its fiscal 2024 third-quarter FFO. The REIT generated free cash flow in excess of dividend payments during the third quarter. Spiking US 10-year Treasury yield forms a material headwind for stock price growth. Read the full article on Seeking AlphaSeeking Alpha • Oct 21
Healthpeak: Potential Upside Still Exists, But Don't Expect Much
Summary Healthpeak Properties is a BBB+ rated healthcare REIT with a solid portfolio, low leverage, and a well-covered 5.4% yield, offering a conservative 15% annualized return. The company is nearing full valuation but remains attractive due to its stable fundamentals, slight growth prospects, and recent merger benefits. Despite low growth estimates, Healthpeak's conservative P/AFFO of 14.25x suggests a potential upside, making it a "Buy" with a $27/share price target. Healthpeak fulfills all my investment criteria except being cheap, making it a sound investment for conservative, double-digit returns. Read the full article on Seeking Alpha
새로운 내러티브 • Aug 21
Strategic Mergers And Key Life Science Leases Propel Revenue And Earnings Growth
Execution of priorities like merger integration and asset sales directly boosts 2024 guidance, signaling positive revenue and earnings impact.Seeking Alpha • Jul 18
Healthpeak: Missing The Boat Above $20/Share
Summary I update on investment in Healthpeak REIT, owning a significant stake with a positive return on investment and yield of over 7%. I highlight the undervaluation of Healthpeak, positive outlook on a diverse portfolio, and caution on current share price above $20. I maintain my thesis on Healthpeak as an attractive buy with conservative double-digit upside potential, based on sound fundamentals and future growth prospects. Read the full article on Seeking AlphaSeeking Alpha • Jul 09
Healthpeak Properties: A 6.1% Yielding Healthcare Trust With Upside
Summary Healthpeak Properties is a leading U.S. real estate investment trust focused on medical office buildings, poised for long-term growth. The merger with Physician Realty Trust has increased the trust's portfolio to 748 properties, with potential for $80 million in synergies. With a steady dividend and strong funds from operations growth, Healthpeak Properties is a compelling investment for passive income investors. Read the full article on Seeking AlphaSeeking Alpha • May 14
Healthpeak Q1 - The "Best" In The Space With A 15% Upside
Summary Healthpeak (DOC) is an attractive healthcare REIT with a diverse portfolio and a yield of over 7%. The company is unlikely to see significant near-term AFFO growth, but offers stability and potential slight growth. The stock is currently undervalued and has a conservative double-digit upside, making it a good buy. Read the full article on Seeking AlphaSeeking Alpha • Apr 12
HealthPeak Properties: A Quality Healthcare REIT That Should Get Back To Dividend Growth
Summary HealthPeak Properties recently closed on its merger with Physicians Realty Trust, which is expected to generate merger-related synergies and be accretive to AFFO. The company reported strong earnings with solid growth in same-store NOI and AFFO. HealthPeak Properties has a strong balance sheet and attractive valuation below peers and the sector median, offering dividend investors a good buying opportunity. Due to the recent merger, I expect the REIT to get back to dividend growth in the near future. The share price may continue to experience volatility due to shrinking sentiment surrounding interest rate cuts in June. Read the full article on Seeking Alpha주주 수익률
| DOC | US Health Care REITs | US 시장 | |
|---|---|---|---|
| 7D | 3.1% | 4.8% | 1.4% |
| 1Y | 20.1% | 40.3% | 19.1% |
수익률 대 산업: DOC은 지난 1년 동안 40.3%의 수익을 기록한 US Health Care REITs 산업보다 저조한 성과를 냈습니다.
수익률 대 시장: DOC은 지난 1년 동안 19.1%의 수익을 기록한 US 시장과 동일한 성과를 보였습니다.
주가 변동성
| DOC volatility | |
|---|---|
| DOC Average Weekly Movement | 6.1% |
| Health Care REITs Industry Average Movement | 4.0% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.2% |
안정적인 주가: DOC는 지난 3개월 동안 US 시장에 비해 주가 변동성이 크지 않았습니다.
시간에 따른 변동성: DOC의 주간 변동성(6%)은 지난 1년 동안 안정적이었습니다.
회사 소개
| 설립 | 직원 수 | CEO | 웹사이트 |
|---|---|---|---|
| 1985 | 411 | Scott Brinker | www.healthpeak.com |
는 미국에서 의료 서비스 발견 및 제공에 중점을 둔 고품질 부동산을 소유, 운영 및 개발하는 스탠더드앤드푸어스 500대 기업입니다. 당사는 원래 1985년에 설립되었습니다. 당사는 엄브렐러 파트너십 리츠로 조직되어 있습니다.
Healthpeak Properties, Inc. 기초 지표 요약
| DOC 기초 통계 | |
|---|---|
| 시가총액 | US$15.20b |
| 순이익 (TTM) | US$221.63m |
| 매출 (TTM) | US$2.87b |
68.1x
주가수익비율(P/E)5.3x
주가매출비율(P/S)DOC는 고평가되어 있습니까?
공정 가치 및 평가 분석 보기순이익 및 매출
| DOC 손익계산서 (TTM) | |
|---|---|
| 매출 | US$2.87b |
| 매출원가 | US$1.20b |
| 총이익 | US$1.68b |
| 기타 비용 | US$1.45b |
| 순이익 | US$221.63m |
최근 보고된 실적
Mar 31, 2026
다음 실적 발표일
Aug 04, 2026
| 주당순이익(EPS) | 0.32 |
| 총이익률 | 58.33% |
| 순이익률 | 7.72% |
| 부채/자본 비율 | 115.0% |
DOC의 장기 실적은 어땠습니까?
과거 실적 및 비교 보기배당
5.6%
현재 배당 수익률68%
배당 성향기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/07/02 15:17 |
| 종가 | 2026/07/02 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Healthpeak Properties, Inc.는 36명의 분석가가 다루고 있습니다. 이 중 10명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Jacob Kilstein | Argus Research Company |
| David Rodgers | Baird |
| Adam Feinstein | Barclays |